P/E ratio for NeoGenomics (NEO)
P/E ratio as of June 2025 (TTM): -11.5
According to NeoGenomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.4836. At the end of 2024 the company had a P/E ratio of -26.6.
P/E ratio history for NeoGenomics from 2004 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -26.6 | |
| 2022 | -7.97 | -98.68% |
| 2021 | -604 | -133.66% |
| 2020 | > 1000 | 329.49% |
| 2019 | 418 | 111.36% |
| 2018 | 198 | -412.39% |
| 2017 | -63.3 | 188% |
| 2016 | -22.0 | -87.44% |
| 2015 | -175 | -192.61% |
| 2014 | 189 | 161.31% |
| 2013 | 72.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 RadNet RDNT | -101 | 779.20% | 🇺🇸 USA |
 Psychemedics PMD | -3.75 | -67.33% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 22.4 | -295.25% | 🇺🇸 USA |
 LabCorp LH | 30.0 | -361.08% | 🇺🇸 USA |
 Enzo Biochem ENZB | -2.32 | -79.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.